PURPOSE OF REVIEW: We review and offer our clinical perspectives on the emergence of echinocandin-resistant Candida. RECENT FINDINGS: Candida FKS gene mutations attenuate echinocandin activity, but overall mutation rates among clinical isolates remain low (Candida glabrata, ∼4%; other species, <1%). Rates are higher with prior echinocandin exposure, exceeding 50% among C. glabrata or Candida albicans isolates causing breakthrough invasive candidiasis. The median duration of prior echinocandin exposure among FKS mutant isolates is ∼100 days. The clinical usefulness of echinocandin susceptibility testing is limited by the low overall prevalence of resistance, and uncertainties surrounding testing methods and interpretation of minimum inhibitory concentrations (MICs). In single-center studies, caspofungin resistance (defined using institution-specific MIC breakpoints) was 32-53% sensitive and 75-95% specific for predicting treatment outcomes of C. glabrata invasive candidiasis; corresponding values for the presence of an FKS mutation were 35-41% and 90-98%. Results were similar using anidulafungin and micafungin MICs. Clinical data are scarce for non-C. glabrata species. SUMMARY: Echinocandins remain preferred agents against invasive Candida infections. Susceptibility testing and FKS genotypic testing do not have roles in routine clinical practice, but may be useful in newly-diagnosed patients who are echinocandin-experienced or those who have not responded to echinocandin treatment.
PURPOSE OF REVIEW: We review and offer our clinical perspectives on the emergence of echinocandin-resistant Candida. RECENT FINDINGS:Candida FKS gene mutations attenuate echinocandin activity, but overall mutation rates among clinical isolates remain low (Candida glabrata, ∼4%; other species, <1%). Rates are higher with prior echinocandin exposure, exceeding 50% among C. glabrata or Candida albicans isolates causing breakthrough invasive candidiasis. The median duration of prior echinocandin exposure among FKS mutant isolates is ∼100 days. The clinical usefulness of echinocandin susceptibility testing is limited by the low overall prevalence of resistance, and uncertainties surrounding testing methods and interpretation of minimum inhibitory concentrations (MICs). In single-center studies, caspofungin resistance (defined using institution-specific MIC breakpoints) was 32-53% sensitive and 75-95% specific for predicting treatment outcomes of C. glabratainvasive candidiasis; corresponding values for the presence of an FKS mutation were 35-41% and 90-98%. Results were similar using anidulafungin and micafungin MICs. Clinical data are scarce for non-C. glabrata species. SUMMARY:Echinocandins remain preferred agents against invasive Candida infections. Susceptibility testing and FKS genotypic testing do not have roles in routine clinical practice, but may be useful in newly-diagnosed patients who are echinocandin-experienced or those who have not responded to echinocandin treatment.
Authors: A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge Journal: Antimicrob Agents Chemother Date: 2013-09-09 Impact factor: 5.191
Authors: O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann Journal: Clin Microbiol Infect Date: 2012-12 Impact factor: 8.067
Authors: M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; R N Jones; J Turnidge; D J Diekema Journal: J Clin Microbiol Date: 2009-11-18 Impact factor: 5.948
Authors: Guillermo Garcia-Effron; Santosh K Katiyar; Steven Park; Thomas D Edlind; David S Perlin Journal: Antimicrob Agents Chemother Date: 2008-04-28 Impact factor: 5.191
Authors: Ryan K Shields; M Hong Nguyen; Ellen G Press; Cassaundra L Updike; Cornelius J Clancy Journal: Antimicrob Agents Chemother Date: 2013-09-23 Impact factor: 5.191
Authors: Maiken C Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William W Hope Journal: Drug Resist Updat Date: 2014-01-27 Impact factor: 18.500
Authors: Kristy Koselny; Julianne Green; Louis DiDone; Justin P Halterman; Annette W Fothergill; Nathan P Wiederhold; Thomas F Patterson; Melanie T Cushion; Chad Rappelye; Melanie Wellington; Damian J Krysan Journal: Antimicrob Agents Chemother Date: 2016-11-21 Impact factor: 5.191
Authors: M A De Francesco; G Piccinelli; M Gelmi; F Gargiulo; G Ravizzola; G Pinsi; L Peroni; C Bonfanti; A Caruso Journal: Mycopathologia Date: 2017-06-08 Impact factor: 2.574
Authors: Ryan K Shields; Ellen G Kline; Kelley R Healey; Milena Kordalewska; David S Perlin; M Hong Nguyen; Cornelius J Clancy Journal: Antimicrob Agents Chemother Date: 2018-12-21 Impact factor: 5.191
Authors: Paula McCourt; Hsing-Yin Liu; Josie E Parker; Christina Gallo-Ebert; Melissa Donigan; Adam Bata; Caroline Giordano; Steven L Kelly; Joseph T Nickels Journal: G3 (Bethesda) Date: 2016-11-08 Impact factor: 3.154